Many organisms, ranging from plants to mammals, contain phospholipase A 2 enzymes (PLA 2 s), which catalyze the production of lysophospholipids and fatty acid proinflammatory mediators. PLA 2 s are also common constituents of animal venoms, including bees, scorpions and snakes, and they cause a wide variety of toxic effects including neuro-, myo-, cyto-, and cardio-toxicity, anticoagulation and edema. The aim of this study was to develop a generic method for profiling enzymatically active PLA 2 s in snake venoms after chromatographic separation. For this, low-volume high-throughput assays for assessment of enzymatic PLA 2 activity were evaluated and optimized. Subsequently, the assays were incorporated into a nanofractionation platform that combines high-resolution fractionation of crude venoms by liquid chromatography (LC) with bioassaying in 384-well plate format, and parallel mass spectrometric (MS) detection for toxin identification. The miniaturized assays developed are based on absorbance or fluorescence detection (respectively, using cresol red or fluorescein as pH indicators) to monitor the pH drop associated with free fatty acid formation by enzymatically active PLA 2 s. The methodology was demonstrated for assessment of PLA 2 activity profiles of venoms from the snake species Bothrops asper, Echis carinatus, Echis coloratus, Echis ocellatus, Oxyuranus scutellatus and Daboia russelii russelii.
Introduction
Phospholipase A 2 (PLA 2, EC 3.1.1.4) is a common enzyme occurring in many organisms, ranging from plants to mammals. [1] PLA 2 s are crucial enzymes in lipid metabolism and lipid-protein interactions. They also play a significant role in various cellular processes such as biotransformation and digestion of phospholipids, signal transduction and host defense. [2] PLA 2 s are connected to human pathophysiological events and associated with certain types of cancers, arthritis, and inflammatory disorders, and therefore have been studied extensively. [3] [4] [5] PLA 2 s are also widely distributed in animal venoms. Snake venom PLA 2 s (svPLA 2 s) can be major toxin components -they often comprise 30-71% of the total venom proteins, and they can also be diverse in terms of amino acid composition, as evidenced by the UniProtKB database containing over 400 unique svPLA 2 s. [6] In addition to catalyzing the production of lysophospholipids and fatty acid pro-inflammatory mediators, svPLA 2 s are multifunctional enzymes and cause a wide variety of toxic effects ranging from neurotoxicity, myotoxicity, anticoagulant effects, cytotoxicity, cardiotoxicity, to edema. [7] Because of the pathological consequences of these toxins to prey and snakebite victims, svPLA 2 s have been extensively investigated. [7, 8] Since May 2018, snake envenoming has been categorized as one of the most neglected tropical diseases. [9] The annual number of human snakebites is estimated to be between 1.8 and 2.7 million worldwide, resulting in 81,000-138,000 deaths and around three times more cases of permanent morbidity cases. [10] Many victims receive inadequate treatment or no treatment at all. The World Health Organization (WHO) has therefore adopted a resolution towards tackling this devastating global health problem. [10] Snake venoms are complex biochemical mixtures that are injected via the fangs of snakes for killing prey and for defense. These venoms comprise many different pathological proteins and peptides, and other organic molecules. Venom composition is typically complex (50-200 proteins per species) and highly variable, with often extensive inter-specific, and even, intra-specific venom variations observed. [11, 12] Rooted in the latter are geographical differences, living habitat, sex, and age of a snake, thereby increasing venom complexity even more. [13, 14] Consequently, antivenom therapies, which are based on antibodies produced in horses or sheep following their immunization with venom or mixtures of venoms, are highly specific to those venoms used for production, but often lack efficacy for treating snakebites by other snake species. [12] In recent years, research efforts have increased on the potential utility of small molecule drugs as potential alternatives for conventional antivenom therapies. These promising approaches focus on neutralizing entire classes of venom enzymes, irrespective of sequence and structural variation, with small molecular inhibitors or metal chelators. For instance, recent studies have demonstrated that enzyme inhibitors and metal chelating agents, such as EDTA and DMPS, are capable of neutralizing snake venom metalloproteinase toxins in pre-clinical models of envenoming. [15, 16] In relation to svPLA 2 s, a number of studies have explored the neutralizing potential of the generic PLA 2 inhibitors methyl-varespladib and varespladib. [17] These compounds show great promise for the future development of affordable, stable and broad-spectrum treatment for PLA 2 -induced toxicities following snake envenoming.
However, as svPLA 2 s are major venom toxins responsible for a diverse array of severe pathologies following envenoming, the development of analytics for rapid svPLA 2 profiling after chromatographic separation of snake venoms -the approach described in this studyis an essential prerequisite for efficient selection and in vitro validation of novel PLA 2 inhibiting agents.
Assays using chromogenic molecules for PLA 2 profiling have previously been developed. [18, 19] One of these assays relies on hydrolysis of a substrate by PLA 2 s into a coloured product, with ensuing absorbance measured at 425 nm, as described by Petrovic et al. [18] In addition, both radioactivity based assays [20, 21] and fluorogenic assays [22, 23] have been described. All these assay formats, however, are probe substrate dependent and thus dependent on the selectivity and enzymatic activity of each PLA 2 for the probe substrate used. Assays for assessment of generic enzymatic PLA 2 activity use a phospholipid as a generic substrate, in combination with pH indicators to measure medium acidification upon phospholipid hydrolysis. [24] [25] [26] This enzymatic reaction involves PLA 2 s cleaving the sn-2 ester of phospholipids, generating a free fatty acid and a lyso-phosholipid.
Price et al. and Lobo De Araljio et al. measured PLA 2 activity of crude snake venoms using the pH indicators bromothymol blue [26] and phenol red [27] , respectively. These assays were performed in cuvettes, using a spectrophotometer, or in 96-well format. The use of bromothymol blue in a PLA 2 assay was considered for this study, but was abandoned since literature reports this pH indicator to be able to inhibit phospholipase subunits under certain conditions. [27] In this study, two assays for enzymatic PLA 2 activity were developed in 384-well format. One assay makes use of cresol red with colorimetric readout whereas the other uses fluorescein with fluorescence readout. The assays were optimized and validated for application in a workflow comprising high-resolution chromatographic fractionation of snake venoms followed by enzymatic PLA 2 bioassaying. For this, well plates with collected fractions were vacuum-centrifuged to dryness followed by robotic pipetting of bioassay reagents and plate reader based readout in order to assess PLA 2 activities. The feasibility and usefulness of the approach for measuring generic svPLA 2 activity profiles was demonstrated using medically relevant snake venoms from Bothrops asper, Echis carinatus, Echis coloratus, Echis ocellatus, Oxyuranus scutellatus and Daboia russelii russelii.
Materials and Methods

Chemicals and biological reagents
Water was purified with a Milli-Q Plus system (Millipore, Amsterdam, The Netherlands).
DMSO was supplied by Riedel-de-Haën (Zwijndrecht, The Netherlands). Acetonitrile (ACN; ULC/MS grade) and formic acid (FA) were obtained from Biosolve (Valkenswaard, The Netherlands). All salts used for buffer preparation were of analytical grade and purchased from Merck (Kenilworth, USA), Fluka (Bucharest, Romania) or Sigma-Aldrich (Darmstadt, Germany). Micro-90 ® concentrated cleaning solution was supplied by Sigma-Aldrich.
Lyophilised snake venoms (see Table 1 ) were provided by the Centre for Snakebite
Research & Interventions (Liverpool School of Tropical Medicine, UK) and stored long-term at -80 °C. Stock solutions of crude venoms (5.0 mg/mL) were prepared in water prior to analysis and stored at -80 °C. A 1 mM Tris (pH 8) buffer solution for the bioassay was made in Milli-Q water and its pH was checked at room temperature. After preparation, the buffer was stored at 4 °C until use. Cresol red and fluorescein were from Sigma-Aldrich. The 5 mM cresol red stock solution was prepared in methanol and stored at -20 °C. The 1 mM fluorescein stock solution was prepared in DMSO and kept at -80 °C. Triton-X-100 was purchased from Thermo Scientific (Landsmeer, Netherlands) and a stock solution of 170 mM was prepared in milli-Q water and stored at -20 °C. Phosphatidylcholine from soy beans was purchased from Sigma-Aldrich of which a stock solution of 20 mg/mL was prepared in methanol and kept at -20 °C. 
PLA 2 assay using cresol red as pH indicator
Pre-prepared 1.0 mM TRIS buffer solution was used at room temperature and pH 8.0. The assay was performed with all other reagents at room temperature, which is crucial due to the pH dependence of the assay. For best performance the assay reagent mix was freshly For the latter, one measurement data point was plotted every 10 min over the total measuring curve. For constructing bioassay chromatograms of snake venoms, for each well the value resulting from the processed assay data was plotted against the LC elution time corresponding to the well.
PLA 2 assay using fluorescein as pH indicator
In this PLA 2 activity assay fluorescein is used as a fluorescent pH indicator in black 384-well, F-shape microplates (Greiner Bio One, Alphen aan den Rijn, the Netherlands). A decrease in assay pH causes a decrease of fluorescence intensity. Concentrations and preparation of the assay reagents and mix were the same as for the colorimetric assay (Section 2.2), but no Cresol Red was added. Instead, fluorescein was present at a final concentration of 1 µM.
The assay was started by using the same procedure as stated in Section 2.2. The plate reader temperature was set at 25 ˚C and of each well fluorescence was measured using an excitation wavelength of 488 nm and an emission wavelength of 520 nm in the Varioskan™ LUX Multimode Microplate Reader. Measurements were performed in one kinetic loop with a total measurement time of 40 min. The bioassay data were presented as bioassay chromatograms when used for snake venom screening.
The cleaning procedure of the robotic pipetting machine is as reported previously in Still et al. [28] For typical kinetic curve results obtained when running both PLA 2 assay formats with venoms high in PLA 2 abundance, the reader is referred to supporting information S1. The difference in curve slopes allows for the reconstruction of bioactivity chromatograms (more details in Section 3.3).
Instrumental setup for venom fractionation
For high-resolution fractionation of snake venoms, the analytical system previously described by Still et al. [28] and by Mladic et al. [29] was used. Samples were injected with a Shimadzu SIL-30AC autosampler and LC separation was performed with a Shimadzu LC system controlled by Lab Solutions software. Gradient LC was performed using two 
Results and Discussion
This research focused on the development and optimization of enzymatic PLA 2 activity assays suitable for application in the nanofractionation platform to allow profiling of venom fractions. For this, these assays should be sensitive, rapid, robust, and applicable to small LC fractions (collected in 384-well plate format). PLA 2 catalyzes the hydrolysis of ester bonds of glycerophospholipids at position sn-2. PLA 2 activity assaying can be based on the accompanying acidification of the reaction mixture caused by the formed free fatty acids during phosphatidylcholine hydrolysis. In presence of pH indicators, activity will cause measurable color changes. The use of bromothymol blue in the required miniaturized assay was considered for use in this study, however, (i) the literature reports this pH indicator to inhibit phospholipase subunits, [26] while pilot experiments using bromothymol blue for assaying venoms showed highly varying and non-repeatable results. Specifically, our pilot results appeared unrelated to PLA 2 hydrolysis of phosphatidylcholine, and therefore bromothymol blue was not considered to be suitable for our purposes. Instead, we developed two assays suitable for 384-well format using phosphatidylcholine as a substrate, with either cresol red (CR) as a color pH indicator or fluorescein as a fluorescent pH indicator.
PLA 2 activity assay based on cresol red
Assay optimization
Going from pH 8.8 to 7.0, protonation of the pH indicator cresol red results in a color change from red to yellow. When cresol red is added to the assay reagent mixture, PLA 2 activity can be detected as a decrease in absorbance at 572 nm. [25, 27] The pH of the assay solution was first adjusted to 8.0 in order to allow sensitive detection of the pH shift.
Optimal conditions were studied and achieved in several optimization steps, as described below. More detailed information and results on the development of the cresol red-based PLA 2 activity assay are provided in the supporting information S2 and S3.
The optimal concentrations for cresol red and the substrate phosphatidylcholine were studied by performing serial dilution experiments. Daboia russelii russelii (DRR) snake venom, which is known for its relatively high content of svPLA 2 , was used as a test venom for assay optimization at a concentration of 12.5 µg/mL. [11] Figure 1 shows time-course absorbance measurements in a cuvette using optimized assay conditions and DRR venom. 
Counts (absorbance)
The color change of cresol red over time is observed as an increasing absorbance at 430 nm and a decreasing absorbance at 570 nm. As the absolute change is most substantial at 570 nm, this wavelength was used for the readout of the cresol red-based PLA 2 assay. Higher concentrations of cresol red resulted in more intense red coloring of the assay mixture, detected as a higher absorbance at 572 nm at the start of the measurement ( Figure S2 ).
The optimal cresol red concentration was found to be 37 µM. Increasing the concentration of phosphatidylcholine resulted in an increased acidification of the assay mixture upon assay progression when svPLA 2 s were present. The optimal substrate concentration was determined to be 0.66 mM. Concentrations of 0.66 mM and 37 µM for phosphatidylcholine and cresol red, respectively, were used in all subsequent experiments. Absorbance (572 nm)
Assay evaluation
The optimized assay was evaluated for sensitivity and limit of detection (LOD) by analyzing different concentrations of DRR snake venom.
The concentration-response plot for svPLA 2 activity was assessed by analyzing a serial dilution series of DRR venom in water (freeze-dried after addition to the wells) with final assay concentrations of 50, 25, 12.5, 6.3 and 3.2 μg/mL ( Figure 2 ). The starting steepness of the declining curve is correlated to the DRR venom concentration and thus the overall activity of svPLA 2 s present in the assay mixture. Note that the starting point of the kinetic measurement is the moment the plate reader measurement is initiated and thus does not represent the real starting point, which is the moment the assay mix is pipetted to the venom. As can be seen, increasing DRR concentrations resulted in faster declines in absorbance over time (Figure 2) . Also, the higher the concentration of DRR the lower the absorbance of the first measured point due to the initial faster enzymatic conversion rates. Therefore, after pipetting the assay mix to a well plate, the assay readout 
PLA 2 assay based on fluorescein
Assay development
The fluorescence quantum yield of fluorescein is pH dependent, being highest at around pH 8. Its fluorescence decreases in the presence of lowered pH, which is the detection principle of the fluorescence assay format. Below pH 6 the emission starts to get weak, and becomes undetectable at very acidic conditions. [30, 31] For this assay a Tris buffer of pH 8 was chosen (as for cresol red) and the decrease of fluorescence intensity of fluorescein was monitored as result of PLA 2 activity causing a drop in pH. [30, 31] Additional information and results on the optimization of the fluorescein-based PLA 2 activity assay is provided in Section S4 of the supporting information. Different fluorescein concentrations were tested (final concentrations: 0.2, 0.5, 1.0, and 5.0 µM). The same phosphatidylcholine concentration as for the cresol red-based assay was used assuming the substrate concentration to be independent of the pH indicator used. Increasing the fluorescein concentration yielded more intense fluorescence signals at the start of a measurement (see Figure S4 in the supporting information). The optimal fluorescein concentration was determined to be 1 µM, providing optimal signal-to-noise ratios while achieving acceptable assay repeatability. Concentrations of 1 µM fluorescein and 0.66 mM phosphatidylcholine were used for all subsequent experiments.
Fluorescein PLA 2 assay evaluation
The optimized fluorescein-based assay was further evaluated for sensitivity and LOD. The DRR serial dilution series was added to different wells and then vacuum centrifuge dried prior to assay pipetting to avoid undesired dilution effects. As with the previous assay, the starting point of the kinetic measurement is the moment the plate reader measurement is initiated and as such thus not the real starting point, which is the moment the assay mix is pipetted to the venom. Therefore, after pipetting the assay mix to a well plate, the assay readout was started as soon as possible. Increased DRR concentrations resulted in increased progression of the svPLA 2 s enzymatic activity visible as declined fluorescent intensities observed at the first measurement point of the curves. The last measurement point for the two highest DRR concentrations tested (12.5 µg/mL and 6.3 µg/mL) almost overlapped, indicating a smaller assay window for the fluorescein-based assay as compared to the cresol red assay when performing an end-point measurement. The results also show that the fluorescein assay was more sensitive than the cresol red assay for DRR venom.
With this assay, clear hydrolyzation was already observed within 10 minutes at a DRR concentration of 1.6 μg/mL. In the fluorescein assay, a concentration of 0.8 μg/mL DRR still gave a measurable effect after 40 minutes.
The fluorescein-based assay was then evaluated for specificity for PLA 2 To summarize the two approaches compared here, the PLA 2 assay using cresol red facilitates measuring a wider range of PLA 2 concentrations in comparison with the fluorescein-based assay. However, the latter assay is more sensitive. Figure 6 : Kinetic fluorescence measurements obtained for assessing the inhibitory effect of the PLA 2 inhibitor varespladib on the fluorescein based PLA 2 assay. Concentrations of phosphatidylcholine, fluorescein, and DRR were 0.66 mM and 1 μM, and 1.6 μg/mL, respectively. The assay was performed in presence of varespladib with final concentrations of 50, 5.0, 0.5, 0.05, and 0 μM. Fluorescence was measured using an excitation wavelength of 488 nm and an emission wavelength of 520 nm. Each curve represents the mean of two measurements and the error bars represent SEMs.
Coupling of the two PLA 2 assay formats with nanofractionation analytics
Finally, the two developed assays were incorporated into the nanofractionation analytics platform. This allowed for obtaining bioactive PLA 2 profiles of snake venoms after chromatographic separation. svPLA 2 s are derived from members of the sPLA 2 family, which are found in mammals and other vertebrates. It is said that the genes expressing svPLA 2 s have undergone gene duplication and accelerated evolution over evolutionary time, which has resulted in structural, functional, and expressional level variations of svPLA 2 s isoforms. [14, 32] As such, many snake venoms are known to contain a number of different svPLA 2 isoforms. The presence of these isoforms, and their abundances, can thus vary greatly according to species, but also according to, for example, population, age and sex of a snake, and (prey) ecology. [33] [34] [35] The generic svPLA 2 tertiary structure, may contain up to seven disulfide bridges. This means that for an enzyme, svPLA 2 s are considered to be rather stable and are therefore relatively resistant to heat, organic solvents, and acidic conditions. [17] These properties, their high abundance in many snake venoms, and their relatively low molecular weight (~13 to 15 kDa) is advantageous for their intact isolation/fractionation using reversed phase liquid chromatography (RPLC) thereby allowing subsequent characterization and bioactivity profiling. [36, 37] The nanofractionation analytics platform connects chromatographic separations of venoms with UV data collection, optionally mass spectrometry, and high-resolution fractionation on well plates followed by bioassaying. This platform for screening snake venoms has been described earlier by others, including for example Mladic et al. [29] and Still et al. [28] for other assay formats. In this study, snake venoms were separated using RP-LC with a post column split directing 90% of the effluent to a high-resolution fraction collector (e.g. the FractioMate) and 10% to UV and optionally MS. After fraction collection in 384-well plates, the plates were vacuum centrifuged to remove solvents after which one of the two PLA 2 bioassays was performed. After bioassaying, reconstructed bioassay chromatograms were plotted which could then be correlated to UV and MS traces in an effort to identify the enzymatically active svPLA 2 s.
Venom of six snake species were screened for svPLA 2 activity using the cresol red PLA 2 assay and venoms of two snakes were screened using the fluorescein-based PLA 2 assay. The results obtained for the cresol red based assay are shown in Figure 7 . Each experiment was performed in duplicate and both the LC-UV spectral data as well as the chromatographic bioactivity profiles (representing the mean of three measurements) are provided. The bioassay chromatograms were constructed by plotting the calculated slopes of each measured svPLA 2 activity curve of each well against fractionation time. As 6-sec fractions were collected, high resolution reconstructed bioassay chromatograms were obtained. svPLA 2 activity is detected as an increase in the slopes of the kinetic measurements and is svPLA 2 concentration-dependent (e.g. as shown in Figure 3 ). The enzymatic activities of eluted svPLA 2 s are therefore visible in the reconstructed bioassay chromatograms as positive peaks. Each venom analyzed was found to have its own characteristic fingerprint or signature-like LC-UV chromatogram with corresponding bioactivity chromatogram profile. The results displayed in Figure 7 show that the bioactive peaks for all venoms analyzed eluted in the 15 to 25-minute time frame. Later eluting (nonbioactive) peaks may, although not likely for the relatively stable svPLA 2 s, be denaturized svPLA 2 s (due to the high organic solvent (i.e. acetonitrile) concentration during elution). As can be seen from the chromatographic PLA 2 bioactivity data, all the snake venoms analyzed show positive svPLA 2 bioactivity peaks, which indicates that all venoms profiled contain at least one, but in most cases multiple, svPLA 2 s. Bothrops asper venom, several svPLA 2 bioactivities are clearly observed and, when compared to the results obtained from the cresol red assay, additional bioactivities were visualized due to the higher sensitivity of the fluorescein-based assay. After the first set of closely co-eluting svPLA 2 s observed in both assays (between ~17 to 19 minutes), these additional svPLA 2 activities are observed after the first broad peak and eluted as one sharp peak followed by two non-baseline separated bioactivity peaks. Figure 7C ). This negative activity might have resulted from a compound having a basifying effect on the assay mixture's pH. In this specific case it is not expected to have resulted from an activity linked to enzymatic PLA 2 activity. In addition, it is known that svPLA 2 s can display a change in activity (mostly an increase) when enzymatically converting higher-ordered lipid aggregate substrates as compared to monomeric substrates. [38] As such, some svPLA 2 s may show low activity for the phospholipid substrate used in this study. 
Correlation of bioactive peaks with MS and proteomics data for toxin identification
From literature and the database Uniprot (https://www.uniprot.org/) [39] it was found that all snake venoms profiled in this study have multiple known svPLA 2 s. Daboia russelii russelii venom, and 1537.0489 9+ for Echis ocellatus venom. In Figure 7 and 
Conclusion
The PLA 2 assays developed herein were demonstrated to be sensitive and robust and were successfully coupled to nanofractionation analytics to analyze svPLA 2 activity of separated venom toxins. The PLA 2 assay using cresol red was found to have the largest assay window, i.e. being able to detect a larger variation in PLA 2 concentrations, while the fluoresceinbased assay proved to be the most sensitive assay, thereby making both assays complementary to one another. When using C18 RP-LC with nanofractionation analytics for svPLA 2 profiling of snake venoms, reproducible specific fingerprint-like separation profiles were obtained of which bioactive svPLA 2 s showed positive bioactivity peaks in the reconstructed bioactivity chromatograms. As many svPLA 2 s have similar primary sequences, and thus much structural resemblance, overlap of different bioactive svPLA 2 s by co-elution was expected and was indeed observed in this study. Prior accurate mass and proteomics data of some of the venoms used in this study was repurposed here for svPLA 2 identification, and to assess assay and analytical platform performance, resulting in bioactivity chromatograms with tentatively identified enzymatically active svPLA 2 s. We anticipate that our development of new analytics for rapidly profiling svPLA 2 activity will have utility for future research on snakebite pathologies caused by svPLA 2 toxins, and for the identification of novel inhibitory molecules capable of neutralizing svPLA 2 s for their future selection and translation into snakebite therapeutics. 
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